Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth
- 1.1k Downloads
The use of proton pump inhibitors (PPIs) may potentially predispose to the development of small intestinal bacterial overgrowth (SIBO), but this association is controversial due to conflicting results from studies conducted to date. The aim of this meta-analysis was to evaluate the association between the use of PPIs and the risk of SIBO. We systematically searched the online PubMed, Embase, and Cochrane Library databases and Web of Science for relevant articles published up to November 2016. Two researchers identified and extracted data independent of each other. The pooled analysis was performed using the generic inverse-variance random-effects model. Subgroup and sensitivity analysis were conducted to assess the stability and heterogeneity of the pooled results. The risk of publication bias was evaluated by assessing for funnel plot asymmetry and by Egger’s test and Begg’s test. A total of 19 articles met the eligibility criteria for the meta-analysis, reporting on 7055 subjects. The pooled odds ratio (OR) showed a statistically significant association between increased risk of SIBO and PPI use (OR 1.71, 95% confidence interval 1.20–2.43). Subgroup analyses demonstrated an association between SIBO and PPI use in studies that employed small bowel aspirates culture and glucose hydrogen breath tests (GHBT) as diagnostic tests for SIBO. Our meta-analysis suggests that the use of PPI moderately increases the risk of SIBO, thereby highlighting the need for appropriate prescribing of PPIs.
KeywordsSmall intestinal bacterial overgrowth Proton pump inhibitors Irritable bowel syndrome
This work was supported by the Zhejiang Province Key Science and Technology Innovation Team (2013TD13), the National Natural Science Foundation of China (81472214), and the Zhejiang Provincial Medical and Health Research Plan (2015126452).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Bartholow M. Top 200 prescription drugs of 2009. Pharmacy Times. 2010. http://www.pharmacytimes.com/publications/issue/2010/may2010/rxfocustopdrugs-0510.
- 16.Enko D, Kriegshauser G. Functional 13C-urea and glucose hydrogen/methane breath tests reveal significant association of small intestinal bacterial overgrowth in individuals with active Helicobacter pylori infection. Clin Biochem. 2016;50(1-2):46–9.Google Scholar
- 32.Wells GA, Shea B, O’Connell D et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute, OttawaGoogle Scholar
- 36.Ardatskaia MD, Loginov VA, Minushkin ON. Syndrome of bacterial overgrowth in patients with the reduced stomach acid secretion: some aspects of the diagnosis. Eksp Klin Gastroenterol. 2014;12:30–6.Google Scholar
- 43.Hawkey CJ, Richter JE, et al., editors. Textbook of clinical gastroenterology and Hepatology. Hoboken: Wiley; 2012.Google Scholar
- 48.Abbasi MH, Zahedi M, Moghadam SD, et al. Small bowel bacterial overgrowth in patients with irritable bowel syndrome: the first study in iran. Middle East. J Dig Dis. 2015;7(1):36–40.Google Scholar